Leading Life Sciences Companies Expand in White City Place — White City Place
Adaptate Biotherapeutics Founded to Develop Cancer Immunotherapies
IONTAS and Adaptate Biotherapeutics Collaborate to Identify Optimized Antibodies for Novel Cancer Targets | Lab Manager
Adaptate Biotherapeutics appoints Dr Mihriban Tuna as Chief Scientific Officer | The Scientist Magazine®
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors | Business Wire
Adaptate Biotherapeutics Company Profile: Valuation, Investors, Acquisition | PitchBook
IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets | World Pharma Today
Adaptate Biotherapeutics | LinkedIn
Adaptate partners with Iontas
Adaptate Biotherapeutics - Crunchbase Company Profile & Funding
Milestone: White City Place W12
Takeda adquiere Adaptate Biotherapeutics para desarrollar nuevas terapias de activación de células T gamma delta dirigidas a tumores sólidos
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells - Pharma Journalist
Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2022 Based on Therapeutic Areas
Dr Mihriban Tuna appointed Chief Scientific Officer at new biotechnology start-up - News & insight - Cambridge Judge Business School
Tim Haines auf LinkedIn: Takeda to acquire Adaptate Biotherapeutics
Takeda aquiere Adaptate Biotherapeutics | Pharmabiz.NET
Natalie Mount - Non-Executive Director at Rinri Therapeutics | The Org
Takeda ups portfolio with Adaptate buy - BioProcess InsiderBioProcess International
Takeda to acquire Adaptate for novel T-cell engager technology
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells | Business Wire
IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets
Andy Chi on LinkedIn: Takeda to Acquire Adaptate Biotherapeutics to Develop Novel GammaDelta…
Frontiers | Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
